Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: A prospective study using T2* cardiovascular magnetic resonance

British Journal of Haematology

Volumn 127, Issue 3, 2004, Pages 348-355

  Anderson, Lisa J ^a   Westwood, Mark A ^a   Holden, Sally ^b   Davis, Bernard ^b   Prescott, Emma ^c   Wonke, Beatrix ^c   Porter, John B ^b   Walker, J Malcolm ^b   Pennell, Dudley J ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c WHITTINGTON HOSPITAL   (United Kingdom)

Author keywords

thalassaemia; Cardiology; Chelator; Iron overload; Magnetic resonance imaging

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEFERIPRONE; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRON;

ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; IRON STORAGE; LIVER; LIVER CLEARANCE; MALE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; THALASSEMIA MAJOR; TINNITUS;

ADULT; CARDIOMYOPATHIES; CASE-CONTROL STUDIES; DEFEROXAMINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; PROSPECTIVE STUDIES; THALASSEMIA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 7944230624     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05202.x     Document Type: Article

References (33)

1. Alfakih, K., Plein, S., Thiele, H., Jones, T., Ridgway, J. & Sivananthan, M. (2003) Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. Journal of Magnetic Resonance Imaging, 17, 323-329.
2. Anderson, L.J., Holden, S., Davis, B., Prescott, E., Charrier, C.C., Bunce, N., Firmin, D.N., Wonke, B., Porter, J.B., Walker, J.M. & Penneil, D.J. (2001) Cardiovascular T2* magnetic resonance for the early diagnosis of myocardial iron overload. European Heart Journal, 22, 2171-2179.
3. Anderson, L.J., Wonke, B., Prescott, E., Holden, S., Walker, J.M. & Pennell, D.J. (2002) Comparison of effects of oral deferipone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet, 360, 516-520.
4. Bellenger, N.G., Davies, L.C., Francis, J.M., Coates, A.J. & Pennell, D.J. (2000) Reduction in sample size for studies of remodelling in heart failure by the use of cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2, 271-278.
5. Bland, J.M. & Altman, D.G. (2002) Validating scales and indexes. British Medical Journal, 324, 606-607.
6. Borgna-Pignatti, C., Rugolotto, S., De Stefano, P., Piga, A., Di Gregorio, F., Gamberini, M.R., Sabato, V., Melevendi, C., Cappellini, M.D. & Verlato, G. (1998) Survival and disease complications in thalassemia major. Annals of the New York Academy of Science, 850, 227-233.
7. Brittenham, G.M., Farrell, D.E., Harris, J.W., Feldman, E.S., Danish, E.H., Muir, W.A., Tripp, J.H. & Bellon, E.M. (1982) Magnetic-susceptibility measurement of human iron stores. New England Journal of Medicine, 307, 1671-1675.
8. Brittenham, G.M., Griffith, P.M., Nienhuis, A.W., McLaren, C.E., Young, N.S., Tucker, E.E., Allen, C.J., & Farell, D.E. Harris, J.W. (1994) Efficacy of desferrioxamine in preventing complication of iron overload in patients with thalassaemia major. New England Journal of Medicine, 331, 567-573.
9. Collins, W. & Taylor, W.H. (1987) Determination of iron in cardiac and liver tissues by plasma emission spectroscopy. Annals of Clinical Biochemistry, 24, 483-487.
10. Cutler, D.J., Isner, J.M., Bracey, A.W., Hufnagel, C.A., Conrad, P.W., Roberts, W.C., Kerwin, D.M. & Weintraub, A.M. (1980) Hemochromatosis heart disease: an unemphasized cause of potentially reversible restrictive cardiomyopathy. American Journal of Medicine, 69, 923-928.
11. Davis, B.A. & Porter, J.B. (2000) Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood, 95, 1229-1236.
12. Drysdale, J.W. & Munro, J.E. (1966) Regulation of synthesis and turnover of ferritin in rat liver. Journal of Biological Chemistry, 241, 3630-3637.
13. Ehlers, K.H., Giardina, P.J., Lesser, M.L., Engle, M.A. & Hiltgartner, M.W. (1991) Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. Journal of Pediatrics, 118, 540-545,
14. Felker, G.M., Thompson, R.E., Hare, J.M., Hruban, R.H., Clemetson, D.E., Howard, D.L., Baughman, K.L. & Kasper, E.K. (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. New England Journal of Medicine, 342, 1077-1084.
15. Grothues, F., Smith, G.C., Moon, J.C., Bellenger, N.G., Collins, P., Klein, H.U. & Pennell, D.J. (2002) Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. American Journal of Cardiology, 90, 29-34.
16. Halliwell, B. & Gutteridge, J.M.C. (1990) Role of free radicals and catalytic metal ions in human disease: an overview. Methods of Enzymology, 186, 1-85.
17. Henry, W.L. N.A., Wiener, M., Miller, D.R., Canale, V.C. & Piomelli, S. (1978) Echocardiographic abnormalities in patients with transfusion-dependent anaemia and secondary myocardial iron deposition. American Journal of Medicine, 64, 547-555.
18. Hershko, C., Link, G. & Pinson, A. (1987) Modification of iron uptake and lipid peroxidation by hypoxia, ascorbic acid and α-tocopheryl in iron-loaded rat myocardial cell cultures. Journal of Laboratory and Clinical Medicine, 110, 355-361.
19. Kremastinos, D.T., Tiniakos, G., Theodorakis, G.N., Katritsis, D.G. & Toutouzas, P.K. (1995) Myocarditis in beta-thalassaemia major. A cause of heart failure. Circulation, 91, 66-71.
20. Kremastinos, D.T., Flevari, P., Spyropoulou, M., Vrettou, H., Tsiapras, D. & Stavropoulos-Giokas, C.G. (1999) Association of heart failure in homozygous beta-thalassaemia with the major histocompatibility complex. Circulation, 100, 2074-2078.
21. Link, G., Athias, P., Grynberg, A., Pinson, A. & Hershko, C. (1989) Effect of iron loading on transmembrane potential, contraction and automaticity of rat ventricular muscle cells in culture. Journal of Laboratory and Clinical Medicine, 113, 103-111.
22. Link, G., Pinson, A. & Hershko, C. (1993) Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. Journal of Laboratory and Clinical Medicine, 121, 127-134.
23. Link, G., Pinson, A. & Hershko, C. (1994) Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells. Blood, 83, 2692-2697.
24. Link, G., Tirosh, R., Pinson, A. & Hershko, C. (1996) Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. Journal of Laboratory and Clinical Medicine, 127, 272-278.
25. Marcus, R.E., Davies, S.C., Bantock, H.M., Underwood, S.R., Walton, S. & Huehns, E.R. (1984) Desferrioxamine to improve cardiac function in iron-loaded patients with thalassaemia major. Lancet, 1, 392-393.
26. Miskin, H., Yaniv, I., Berant, M., Hershko, C., Tamary, H. (2003) Reversal of cardiac complications in thalassaemia major by long term intermittent daily intensive iron chelation. European Journal of Haematology, 70, 398-403
27. Nienhuis, A.W., Griffith, P., Strawczynski, H., Henry, W., Borer, J., Leon, M. & Anderson, W.F. (1980) Evaluation of cardiac function in patients with thalassaemia major. Annals of the New York Academy of Science, 344, 384-396
28. Pennell, D.J. & Bland, J.M. (2003) Deferiprone versus desferrioxamine in thalassemia, and T2* validation and utility. Lancet, 361, 182-184.
29. Porter, J.B. (1999) Development of primary hepatocyte cultures for the preclinical evaluation of iron chelators. MD Thesis. University of Cambridge, Cambridge, UK.
30. Rahko, P.S., Salermi, R. & Uretsky, B.F. (1986) Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. Journal of the American College of Cardiology, 8, 436-440.
31. Spirito, P., Lupi, G., Melevendi, C. & Vecchio, C. (1990) Restrictive diastolic abnormalities identified by doppler echocardiography in patients with thalassaemia major. Circulation, 82, 88-94.
32. Voogd, A., Sluiter, W., van Eijk, H.G. & Koster, J.F. (1992) Low molecular weight iron and the oxygen paradox in isolated rat hearts. Journal of Clinical Investigation, 90, 2050-2055.
33. Wacker, P., Halperin, D.S., Balmer-Ruedin, D., Oberhansli, I. & Wyss, M. (1993) Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassaemia major. Chest, 103, 1276-1278